CNS Pharmaceuticals Stock Price, News & Analysis

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has received approval from swissethics for a pivotal study of Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM). This study marks a significant milestone, given GBM's aggressive nature. The trial will enroll approximately 243 patients, comparing Berubicin to lomustine to evaluate overall survival. Additionally, the FDA has granted Fast Track Designation and Orphan Drug Designation for Berubicin, which may expedite its development process and provide marketing exclusivity.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announces participation in the Virtual Investor Roundtable Event on November 18, 2021, at 9:00 AM ET. CEO John Climaco and CMO Sandra L. Silberman will present and engage in a moderated discussion followed by a Q&A session. Investors can submit questions live or pre-submit them via the event website. A live video webcast will be available on the company's website, with a replay accessible for one year. CNS specializes in treatments for brain and CNS cancers, focusing on their lead candidate, Berubicin.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) announced its Berubicin clinical trial's progress by dosing its first patients for recurrent glioblastoma multiforme (GBM), a severe brain cancer. The pivotal trial, involving 243 patients, aims to evaluate Berubicin’s efficacy against lomustine, focusing on Overall Survival as the primary endpoint. Previous Phase 1 results indicated a 44% clinical benefit rate, with safety consistent with other anthracyclines. CEO John Climaco expressed optimism regarding the trial’s potential and the drug's profile, which appears to cross the blood-brain barrier.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced the initiation of patient dosing in its clinical trial for Berubicin, targeting recurrent glioblastoma multiforme (GBM). This phase of the study is crucial as GBM treatment options are limited and standard care is ineffective in ~60% of cases. The trial will randomize approximately 243 patients to evaluate Berubicin's effectiveness against lomustine. Berubicin received Fast Track and Orphan Drug Designations from the FDA, highlighting its potential to address unmet medical needs in GBM.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) reported its financial results for Q2 2021, highlighting a net loss of approximately $3.8 million compared to $2.4 million in Q2 2020, primarily due to increased clinical trial preparation costs. The company commenced patient enrollment for a pivotal trial of Berubicin, its lead drug candidate for recurrent glioblastoma multiforme (GBM), which received Fast Track Designation from the FDA. As of June 30, 2021, CNSP holds approximately $10.5 million in cash, expected to fund operations into Q2 2022.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced significant advancements on July 1, 2021, including the securing of $4.7 million through an ATM offering at an average price of $2.32, extending its cash runway to Q2 2022. The company received Fast Track Designation from the FDA for its lead drug candidate, Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM). Enrollment has begun in a pivotal study aimed at evaluating Berubicin's efficacy and safety, with patient dosing expected to start in Q3 2021, marking key milestones in CNS's clinical and regulatory strategy.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that the FDA granted Fast Track Designation for its investigational drug Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM). This designation accelerates the development process for drugs addressing serious conditions with unmet medical needs. CNS has also received Orphan Drug Designation for Berubicin. The company has initiated patient enrollment for a pivotal study of Berubicin, which showed promising responses in prior trials. This progress highlights a critical step in combating the aggressive nature of GBM.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has been selected for inclusion in the Russell 2000® Index effective June 25, 2021, following the annual reconstitution of the index. This milestone is expected to enhance market awareness as the company advances its clinical programs for glioblastoma multiforme (GBM). The Russell 2000® Index includes approximately 2,000 of the smallest U.S. securities and is widely utilized by investment managers for benchmarking. The addition is anticipated to provide opportunities for increased visibility and value for CNSP.

CNS Pharmaceuticals (NASDAQ: CNSP) announced the start of patient enrollment for a pivotal study on Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM). This trial will include approximately 210 patients across 35 sites in the U.S. and aims to assess Berubicin's efficacy and safety as compared to standard care. The study's primary endpoint is Overall Survival, a critical measure recognized by the FDA. Additionally, Berubicin has received Orphan Drug Designation from the FDA, granting it seven years of marketing exclusivity upon approval.